Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure
- PMID: 37389503
- DOI: 10.1016/j.jchf.2023.05.018
Distinct Impact of Noncardiac Comorbidities on Exercise Capacity and Functional Status in Chronic Heart Failure
Abstract
Background: Noncardiac comorbidities (NCCs) are common in patients with heart failure (HF), but how they jointly affect exercise capacity and functional status is relatively unexplored.
Objectives: This study sought to investigate the cumulative effects of NCC on exercise capacity and functional status in chronic HF.
Methods: Baseline NCC-status was assessed in HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training), IRONOUT-HF (Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure), NEAT-HFpEF (Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction), INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF), and RELAX-HFpEF (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Heart Failure with Preserved Ejection Fraction) trials, and relations with peak Vo2 and 6-minute walk test (6MWT), Kansas City Cardiomyopathy Questionnaire (KCCQ), and all-cause death were determined according to HF type (with reduced vs preserved ejection fraction). Cluster analysis of the different NCCs was performed.
Results: A total of 2,777 patients were evaluated (mean age: 60 ± 13 years; median NCC burden in HF with preserved vs reduced ejection fraction: 3 [IQR: 2-4] vs 2 [IQR: 1-3]; P < 0.001). Obesity played a more important role in HF with preserved ejection fraction in limiting peak Vo2 and 6MWT. There was a progressive decline in peak Vo2, 6MWT, and KCCQ with increasing NCC burden. Cluster analysis revealed 3 NCC clusters: cluster 1: predominance of stroke and cancer; cluster 2: predominance of chronic kidney disease and peripheral vascular disease; and cluster 3: predominance of obesity and diabetes. Patients in cluster 3 had the worst peak Vo2, 6MWT, and KCCQ despite having the lowest N-terminal pro-B-type natriuretic peptide and exhibited diminished response to aerobic exercise training (peak Vo2Pinteraction = 0.045); however, it had similar risk for all-cause death as cluster 1, whereas cluster 2 had higher risk of death than cluster 1 (HR: 1.60 [95% CI: 1.25-2.04]; P < 0.001).
Conclusions: NCC type and burden have a significant and cumulative effect on exercise capacity, occur in clusters, and are associated with clinical outcomes in patients with chronic HF.
Keywords: cluster analysis; comorbidities; exercise capacity; functional status; heart failure.
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures This paper was prepared using deidentified data obtained from the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the National Heart, Lung, and Blood Institute. Dr Martens has received grant support from the Belgian American Educational Foundation and the Frans Van de Werf Fund; and has received consulting fees from AstraZeneca, Abbott, Bayer, Boehringer-Ingelheim, Daiichi Sankyo, Novartis, Novo Nordisk, and Vifor Pharma. Dr Finet has served as an ad honorem consultant for Wolters Kluwer Health (Lexicomp). Dr Tang has received consulting fees from Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, Renovacor, Boston Scientific, WhiteSwell, Kiniksa Pharmaceuticals, and CardiaTec Biosciences; and has received honorarium from Springer Nature for authorship/editorship and American Board of Internal Medicine for exam writing committee participation. Dr Augusto has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment in
-
Noncardiac Comorbidities in Chronic Heart Failure: More Is Worse, What Else Do We Know?JACC Heart Fail. 2023 Oct;11(10):1377-1379. doi: 10.1016/j.jchf.2023.06.011. Epub 2023 Jul 12. JACC Heart Fail. 2023. PMID: 37452804 No abstract available.
Similar articles
-
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.Eur J Heart Fail. 2020 Jun;22(6):1009-1018. doi: 10.1002/ejhf.1788. Epub 2020 Mar 9. Eur J Heart Fail. 2020. PMID: 32150314
-
Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction.JACC Heart Fail. 2023 Nov;11(11):1549-1561. doi: 10.1016/j.jchf.2023.06.031. Epub 2023 Aug 9. JACC Heart Fail. 2023. PMID: 37565977 Free PMC article.
-
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.J Am Coll Cardiol. 2024 Oct 22;84(17):1603-1614. doi: 10.1016/j.jacc.2024.08.023. Epub 2024 Aug 30. J Am Coll Cardiol. 2024. PMID: 39217565 Free PMC article. Clinical Trial.
-
Mechanisms of the Improvement in Peak VO2 With Exercise Training in Heart Failure With Reduced or Preserved Ejection Fraction.Heart Lung Circ. 2018 Jan;27(1):9-21. doi: 10.1016/j.hlc.2017.07.002. Epub 2017 Aug 4. Heart Lung Circ. 2018. PMID: 28870770 Review.
-
INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design.Circ Heart Fail. 2017 May;10(5):e003862. doi: 10.1161/CIRCHEARTFAILURE.117.003862. Circ Heart Fail. 2017. PMID: 28476756 Free PMC article. Review.
Cited by
-
Referral of the heart failure patient from cardiology and internal medicine department: Same patients and same rehabilitative approach?Int J Cardiol Cardiovasc Risk Prev. 2024 Apr 27;21:200277. doi: 10.1016/j.ijcrp.2024.200277. eCollection 2024 Jun. Int J Cardiol Cardiovasc Risk Prev. 2024. PMID: 39118992 Free PMC article. Review. No abstract available.
-
Phenotype-Specific Outcome and Treatment Response in Heart Failure with Preserved Ejection Fraction with Comorbid Hypertension and Diabetes: A 12-Month Multicentered Prospective Cohort Study.J Pers Med. 2023 Jul 31;13(8):1218. doi: 10.3390/jpm13081218. J Pers Med. 2023. PMID: 37623468 Free PMC article.
-
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial.Hypertens Res. 2024 Nov;47(11):3225-3236. doi: 10.1038/s41440-024-01843-z. Epub 2024 Sep 6. Hypertens Res. 2024. PMID: 39242826 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous